Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376325 | 0.81 | PIN1 (0.57) | SMN1; SMN2NPC1RAB9AHSD17B10ALOX15 | |
| SCHEMBL1528433 | 0.81 | PIN1 (0.57) | SMN1; SMN2NPC1RAB9AHSD17B10ALOX15 | |
| SCHEMBL29600612 | 0.79 | PDPK1 (0.46) | SMN1; SMN2NPC1RAB9AHSD17B10KDM4E | |
| SCHEMBL2623420 | 0.78 | KDM4E (0.46) | SMN1; SMN2NPC1RAB9AHSD17B10ALOX15 | |
| SCHEMBL13950333 | 0.78 | KDM4E (0.46) | SMN1; SMN2NPC1RAB9AHSD17B10ALOX15 | |
| SCHEMBL1528334 | 0.76 | POLB (0.67) | SMN1; SMN2NPC1RAB9AHSD17B10ALOX15 | |
| SCHEMBL17279982 | 0.75 | POLB (0.55) | SMN1; SMN2NPC1RAB9AHSD17B10ALOX15 | |
| SCHEMBL27648472 | 0.75 | PIN1 (0.48) | SMN1; SMN2NPC1RAB9AHSD17B10ALOX15 | |
| SCHEMBL13815661 | 0.74 | HSP90AA1 (0.43) | SMN1; SMN2NPC1RAB9AHSD17B10TDP1 | |
| SCHEMBL18405367 | 0.74 | KDM4E (0.42) | SMN1; SMN2NPC1RAB9AHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738033-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20180346451-A1 | TRK INHIBITION | NANTBIO, INC. | 2018-12-06 | — | — | US | disclosed |
| US-9078902-B2 | Triazine derivatives and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2440057-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | Abraxis BioScience, LLC (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010144550-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346451-A1 | TRK INHIBITION | NGFR, NGF, NTRK1 | SMN1; SMN2 1519/4885NPC1 2610/4885RAB9A 3225/4885 |
| US-10738033-B2 | Trk inhibition | NGF, NGFR, NTRK2 | SMN1; SMN2 1979/4885NPC1 2388/4885RAB9A 2881/4885 |
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | MAP3K2, MAP3K5, MAP4K2 | SMN1; SMN2 3260/4885NPC1 3009/4885RAB9A 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.